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Background
The considerable pressure on healthcare systems,
exerted by increasing expenditures for new drugs, urges
specific initiatives, including the development of new
models, to optimize the managed entry of new medi-
cines and guarantee their sustainability.
Objectives
To develop a forecasting model for drug utilization and
expenditure of emerging medicines identified, prioritized
and critically assessed by the Italian Horizon Scanning
Project (IHSP), integrating a cellular automata (CA)
model describing the diffusion process on the market
with the budget impact analysis (BIA), performed before
the market entry of a new drug.
Methods
Selection and critical evaluation of high-impact emerging
medicines. Development of CA and BIA models for emer-
ging drugs, using medical prescription data from the
administrative ARNO-CINECA databases.
Results
The first-in-class emerging anti-diabetic dapagliflozin was
selected and critically evaluated by the IHSP about
12 months before the European Marketing Authorization
(MA). Other competitors already on the market were
identified. A CA model describing the diffusion process of
more than 200 Italian specialties of oral antidiabetic drugs
(ATC A10B), sold between 2000 and 2014 has been devel-
oped and validated.
A protocol for the identification of the real-world target
population in the ARNO-CINECA database was set up on
the grounds of the expected indication for dapaglifozin.
The estimation of the budget impact of dapagliflozin is
ongoing based on the estimation of market shares,
through the application of the CA model, the analysis of
the identified target population and the analysis of the
potential variations in related healthcare costs for the
treatment of type 2 diabetes, after the introduction of
dapagliflozin.
Conclusions
The proposed forecasting model (C-ToBIA model) pre-
dicts the impact of emerging drugs on the National Health
System (NHS), under the sufficient conditions for estim-
ability. The originality of the C-ToBIA model is basically
related to the assessment of emerging drugs 12 months
before the MA date, and the estimation of the diffusion
process and the potential financial impact before market
entry.
The C-ToBIA model will help to timely estimate the
possible utilization pattern of new medicines and their
potential impact on the NHS before their market entry.
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